Furthermore, it will be of great interest to see whether alternative treatment strategies —either through modulation of the inflammasome-mediated IL-1 processing mechanism or through multi-cytokine targeting approaches—will show clinically relevant response rates and acceptable safety profiles in cancer patients. Here, IL1A is linked to cancer.